TC
FSTX

Trium Capital’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Trium Capital’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-679,744
Closed -$4.3M – 96
2022
Q4 		$4.3M Buy
+679,744
New +$3.76M 1.58% 26

Trium Capital's FSTX Position: Q1 2023 in Review

Trium Capital sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 679,744 shares — an estimated $4.3M sold.

Trium Capital first reported a position in FSTX in Q4 2022 and held it in 1 quarter. The position peaked at $4.3M in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Trium Capital reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Trium Capital sold 679,744 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4.3M.
  • Trium Capital first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Trium Capital's F-star Therapeutics, Inc. Common Stock position peaked at $4.3M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Trium Capital's 13F filing for Q1 2023, filed 16 May 2023.